Toxicity Considerations and Treatment Decisions in CRC
Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.
Source: onclive.com
Fresco 2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fresco 2. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fresco 2 Today - Breaking & Trending Today
FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
Source: onclive.com
FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer
Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.
Source: onclive.com
Dr Grieb on the Need for Novel Biomarkers in CRC
Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.
Source: onclive.com